Open Access

Somatostatin prevents lipopolysaccharide‑induced neurodegeneration in the rat substantia nigra by inhibiting the activation of microglia

  • Authors:
    • Lijuan Bai
    • Xique Zhang
    • Xiaohong Li
    • Na Liu
    • Fan Lou
    • Honglei Ma
    • Xiaoguang Luo
    • Yan Ren
  • View Affiliations

  • Published online on: March 13, 2015     https://doi.org/10.3892/mmr.2015.3494
  • Pages: 1002-1008
  • Copyright: © Bai et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Somatostatin (SST) is a neuromodulator which is abundant throughout the central nervous system (CNS) and has a crucial role in neurodegenerative disorders. However, little is known about the effects and mechanisms of SST in dopaminergic (DA) neurons in the context of Parkinson's disease (PD). In the present study, a model of PD was generated by injecting lipopolysaccharide (LPS) into the substantia nigra (SN) of rats in order to investigate the effects of SST on LPS‑induced degeneration of DA in vivo. Intramural injection of LPS resulted in a significant loss of DA neurons, while reduction of neuronal death by SST pretreatment was confirmed using immunohistochemical staining for tyrosine hydroxylase and Nissl. In parallel, immunohistochemical detection of OX‑42 and hydroethidine staining were employed to determine the activation of microglia and production of reactive oxygen species (ROS), respectively. It was found that SST inhibited the LPS‑induced microglial activity and ROS production. ELISA revealed a decreased production of pro‑inflammatory mediators, including tumor necrosis factor‑α, interleukin‑1β and prostaglandin E2 when SST was administered prior to LPS treatment. Western blot analysis showed that LPS‑induced expression of inducible nitric oxide synthase, cyclooxygenase‑2 and nuclear factor κB (NF‑κB) p‑p65 was attenuated by administration of SST prior to LPS application. The results indicated that LPS‑induced loss of nigral DA neurons was inhibited by SST and the observed effects of SST on neuroprotection were associated with suppression of microglial activation and the NF‑κB pathway, ensuing decreases of neuroinflammation and oxidative stress. The present study therefore suggested that SST is beneficial for treating neurodegenerative diseases, such as PD, through inhibiting the activation of microglia.

References

1 

Ramos-Moreno T, Castillo CG and Martinez-Serrano A: Long term behavioral effects of functional dopaminergic neurons generated from human neural stem cells in the rat 6-OH-DA Parkinson’s disease model. Effects of forced expression of BCL-X(L). Behav Brain Res. 232:225–232. 2012. View Article : Google Scholar : PubMed/NCBI

2 

Golbe LI: Young-onset Parkinson’s disease: A clinical review. Neurology. 41:168–173. 1991. View Article : Google Scholar : PubMed/NCBI

3 

Zanon A, Rakovic A, Blankenburg H, et al: Profiling of Parkin-binding partners using tandem affinity purification. PLoS One. 8:e786482013. View Article : Google Scholar : PubMed/NCBI

4 

Choi SH, Joe EH, Kim SU and Jin BK: Thrombin-induced microglial activation produces degeneration of nigral dopami-nergic neurons in vivo. J Neurosci. 23:5877–5886. 2003.PubMed/NCBI

5 

Song DY, Yu HN, Park CR, et al: Down-regulation of microglial activity attenuates axotomized nigral dopaminergic neuronal cell loss. BMC Neurosci. 14:1122013. View Article : Google Scholar : PubMed/NCBI

6 

Yuan L, Wu Y, Ren X, Liu Q, Wang J and Liu X: Isoorientin attenuates lipopolysaccharide-induced pro-inflammatory responses through down-regulation of ROS-related MAPK/NF-κB signaling pathway in BV-2 microglia. Mol Cell Biochem. 386:153–165. 2014. View Article : Google Scholar

7 

Epelbaum J, Guillou JL, Gastambide F, Hoyer D, Duron E and Viollet C: Somatostatin, Alzheimer’s disease and cognition: An old story coming of age? Prog Neurobiol. 89:153–161. 2009. View Article : Google Scholar : PubMed/NCBI

8 

Viollet C, Lepousez G, Loudes C, Videau C, Simon A and Epelbaum J: Somatostatinergic systems in brain: Networks and functions. Mol Cell Endocrinol. 286:75–87. 2008. View Article : Google Scholar

9 

Epelbaum J, Ruberg M, Moyse E, Javoy-Agid F, Dubois B and Agid Y: Somatostatin and dementia in Parkinson’s disease. Brain Res. 278:376–379. 1983. View Article : Google Scholar : PubMed/NCBI

10 

Espino A, Calopa M, Ambrosio S, Ortolà J, Peres J and Navarro MA: CSF somatostatin increase in patients with early parkinsonian syndrome. J Neural Transm Park Dis Dement Sect. 9:189–196. 1995. View Article : Google Scholar : PubMed/NCBI

11 

Tuboly G and Vécsei L: Somatostatin and cognitive function in neurodegenerative disorders. Mini Rev Med Chem. 13:34–46. 2013. View Article : Google Scholar

12 

Chung ES, Chung YC, Bok E, et al: Fluoxetine prevents LPS-induced degeneration of nigral dopaminergic neurons by inhibiting microglia-mediated oxidative stress. Brain Res. 1363:143–150. 2010. View Article : Google Scholar : PubMed/NCBI

13 

Chung ES, Bok E, Chung YC, Baik HH and Jin BK: Cannabinoids prevent lipopolysaccharide-induced neurodegeneration in the rat substantia nigra in vivo through inhibition of microglial activation and NADPH oxidase. Brain Res. 1451:110–116. 2012. View Article : Google Scholar : PubMed/NCBI

14 

Liu M and Bing G: Lipopolysaccharide animal models for Parkinson’s disease. Parkinson’s Dis. 2011:3270892011.

15 

Block ML, Zecca L and Hong JS: Microglia-mediated neuro-toxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 8:57–69. 2007. View Article : Google Scholar

16 

Koppula S, Kumar H, Kim IS and Choi D-K: Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of Parkinson’s disease. Mediators Inflamm. 2012:8239022012. View Article : Google Scholar

17 

Geng Y, Fang M, Wang J, et al: Triptolide down-regulates COX-2 expression and PGE2 release by suppressing the activity of NF-κB and MAP kinases in lipopolysaccharide-treated PC12 cells. Phytother Res. 26:337–343. 2012.

18 

Tansey MG and Goldberg MS: Neuroinflammation in Parkinson’s disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis. 37:510–518. 2010. View Article : Google Scholar :

19 

Minghetti L: Role of COX-2 in inflammatory and degenerative brain diseases. Inflammation in the Pathogenesis of Chronic Diseases. 42. Harris R, Bittman R, Dasgupta D, et al: Springer; Netherlands: pp. 127–141. 2007

20 

Broom L, Marinova-Mutafchieva L, Sadeghian M, Davis JB, Medhurst AD and Dexter DT: Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease. Free Radic Biol Med. 50:633–640. 2011. View Article : Google Scholar

21 

Aoki E, Yano R, Yokoyama H, Kato H and Araki T: Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice. Exp Mol Pathol. 86:57–64. 2009. View Article : Google Scholar

22 

Dexter DT and Jenner P: Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 62:132–144. 2013. View Article : Google Scholar : PubMed/NCBI

23 

Kim SR, Chung ES, Bok E, et al: Prothrombin kringle-2 induces death of mesencephalic dopaminergic neurons in vivo and in vitrovia microglial activation. J Neurosci Res. 88:1537–1548. 2010.

24 

Miller R, James-Kracke M, Sun G and Sun A: Oxidative and inflammatory pathways in Parkinson’s disease. Neurochem Res. 34:55–65. 2009. View Article : Google Scholar

25 

Shen W, Qi R, Zhang J, et al: Chlorogenic acid inhibits LPS-induced microglial activation and improves survival of dopaminergic neurons. Brain Res Bull. 88:487–494. 2012. View Article : Google Scholar : PubMed/NCBI

26 

Park ES, Kim SR and Jin BK: Transient receptor potential vanilloid subtype 1 contributes to mesencephalic dopaminergic neuronal survival by inhibiting microglia-originated oxidative stress. Brain Res Bull. 89:92–96. 2012. View Article : Google Scholar : PubMed/NCBI

27 

Lull M and Block ML: Microglial activation and chronic neuro-degeneration. Neurotherapeutics. 7:354–365. 2010. View Article : Google Scholar : PubMed/NCBI

28 

Hancock D, Martin ER, Vance JM and Scott WK: Nitric oxide synthase genes and their interactions with environmental factors in Parkinson’s disease. Neurogenetics. 9:249–262. 2008. View Article : Google Scholar : PubMed/NCBI

29 

Li M, Dai FR, Du XP, Yang QD and Chen Y: Neuroprotection by silencing iNOS expression in a 6-OHDA model of Parkinson’s disease. J Mol Neurosci. 48:225–233. 2012. View Article : Google Scholar : PubMed/NCBI

30 

Miller JA, Trout BR, Sullivan KA, Bialecki RA, Roberts RA and Tjalkens RB: Low-dose 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine causes inflammatory activation of astrocytes in nuclear factor-κB reporter mice prior to loss of dopaminergic neurons. J Neurosci Res. 89:406–417. 2011. View Article : Google Scholar : PubMed/NCBI

31 

More SV, Kumar H, Kim IS, Song SY and Choi DK: Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson’s disease. Mediators Inflamm. 2013:9523752013. View Article : Google Scholar

32 

Cui YQ, Jia YJ, Zhang T, Zhang QB and Wang XM: Fucoidan protects against lipopolysaccharide-induced rat neuronal damage and inhibits the production of proinflammatory mediators in primary microglia. CNS Neurosci Ther. 18:827–833. 2012. View Article : Google Scholar : PubMed/NCBI

33 

Teismann P: COX-2 in the neurodegenerative process of Parkinson’s disease. Biofactors. 38:395–397. 2012. View Article : Google Scholar : PubMed/NCBI

34 

Phani S, Loike JD and Przedborski S: Neurodegeneration and inflammation in Parkinson’s disease. Parkinsonism Relat Disord. 18(Suppl 1): S207–S209. 2012. View Article : Google Scholar

35 

Kang CH, Jayasooriya RG, Choi YH, Moon SK, Kim WJ and Kim GY: β-Ionone attenuates LPS-induced pro-inflammatory mediators such as NO, PGE2 and TNF-α in BV2 microglial cells via suppression of the NF-κB and MAPK pathway. Toxicol In Vitro. 27:782–787. 2013. View Article : Google Scholar

Related Articles

Journal Cover

July 2015
Volume 12 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Bai, L., Zhang, X., Li, X., Liu, N., Lou, F., Ma, H. ... Ren, Y. (2015). Somatostatin prevents lipopolysaccharide‑induced neurodegeneration in the rat substantia nigra by inhibiting the activation of microglia. Molecular Medicine Reports, 12, 1002-1008. https://doi.org/10.3892/mmr.2015.3494
MLA
Bai, L., Zhang, X., Li, X., Liu, N., Lou, F., Ma, H., Luo, X., Ren, Y."Somatostatin prevents lipopolysaccharide‑induced neurodegeneration in the rat substantia nigra by inhibiting the activation of microglia". Molecular Medicine Reports 12.1 (2015): 1002-1008.
Chicago
Bai, L., Zhang, X., Li, X., Liu, N., Lou, F., Ma, H., Luo, X., Ren, Y."Somatostatin prevents lipopolysaccharide‑induced neurodegeneration in the rat substantia nigra by inhibiting the activation of microglia". Molecular Medicine Reports 12, no. 1 (2015): 1002-1008. https://doi.org/10.3892/mmr.2015.3494